Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Checkpoint Therapeutics Inc (CKPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/27/2025: CKPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.85% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.26M USD | Price to earnings Ratio - | 1Y Target Price 4.33 |
Price to earnings Ratio - | 1Y Target Price 4.33 | ||
Volume (30-day avg) 775637 | Beta 1.42 | 52 Weeks Range 1.38 - 4.50 | Updated Date 03/30/2025 |
52 Weeks Range 1.38 - 4.50 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-20 | When Before Market | Estimate -0.19 | Actual -0.69 |
Profitability
Profit Margin - | Operating Margin (TTM) -79817.02% |
Management Effectiveness
Return on Assets (TTM) -633.94% | Return on Equity (TTM) -1220.38% |
Valuation
Trailing PE - | Forward PE 8.98 | Enterprise Value 218552579 | Price to Sales(TTM) 4750.12 |
Enterprise Value 218552579 | Price to Sales(TTM) 4750.12 | ||
Enterprise Value to Revenue 4650.05 | Enterprise Value to EBITDA -0.54 | Shares Outstanding 54561300 | Shares Floating 21647936 |
Shares Outstanding 54561300 | Shares Floating 21647936 | ||
Percent Insiders 19.83 | Percent Institutions 33.01 |
Analyst Ratings
Rating 4.67 | Target Price 18 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Checkpoint Therapeutics Inc
Company Overview
History and Background
Checkpoint Therapeutics Inc. was founded in 2015 and focuses on the acquisition, development, and commercialization of novel immunotherapies and targeted oncology therapies. They aim to address unmet medical needs with cost-effective therapies.
Core Business Areas
- Drug Development: Checkpoint focuses on developing antibody-based therapeutics for cancer treatment, including checkpoint inhibitors and targeted therapies.
Leadership and Structure
James F. Oliviero serves as the President and CEO. The company operates with a management team focused on clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Cosibelimab: A novel, fully human anti-PD-L1 antibody being developed for various cancers, including cutaneous squamous cell carcinoma (cSCC). Currently awaiting FDA approval. Competitors include anti-PD-1 therapies from Merck (Keytruda) and Regeneron/Sanofi (Libtayo).
- CK-101: An oral epidermal growth factor receptor (EGFR) inhibitor being developed for non-small cell lung cancer (NSCLC). Competitors include Tagrisso from AstraZeneca and other EGFR inhibitors.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and growing market, driven by increasing cancer incidence and advancements in treatment options, particularly immunotherapies and targeted therapies.
Positioning
Checkpoint Therapeutics is a smaller player focused on developing cost-effective alternatives to existing therapies. Their competitive advantage lies in their drug candidates' potential efficacy and cost-effectiveness.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars annually. Checkpoint is targeting specific niches within this market, such as cSCC and EGFR-mutated NSCLC, to gain a foothold.
Upturn SWOT Analysis
Strengths
- Promising drug candidates (Cosibelimab)
- Experienced management team
- Focus on cost-effective therapies
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- No currently marketed products
Opportunities
- Potential FDA approval for Cosibelimab
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
Threats
- Competition from established players
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRK
- REGN
- AZN
Competitive Landscape
Checkpoint Therapeutics faces significant competition from larger, established pharmaceutical companies with greater resources and marketed products. Their strategy relies on differentiating their products based on efficacy, safety, and cost-effectiveness.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited as the company focuses on R&D. Growth is dependent on successful clinical trial results and regulatory approvals.
Future Projections: Future growth is highly uncertain and dependent on the successful commercialization of Cosibelimab and CK-101. Analyst estimates vary widely based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include completing clinical trials for Cosibelimab and preparing for potential FDA submission and launch.
Summary
Checkpoint Therapeutics is a clinical-stage company with promising assets in the oncology space, particularly cosibelimab. Its success hinges on achieving FDA approval and successfully commercializing its products. The company faces competition from established players and requires significant funding to continue its development programs, making it a high-risk, high-reward investment. Future potential exists in achieving regulatory approvals and launching its products into the market.
Similar Companies
- MRK
- REGN
- AZN
- BMY
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Clinical trial data
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual research and consultation with a financial advisor. Market share data is an estimate and may not be precise. Financial data is as of the most recent available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Checkpoint Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2017-06-26 | President, CEO & Director Mr. James F. Oliviero III, C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://checkpointtx.com |
Full time employees 23 | Website https://checkpointtx.com | ||
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.